364 related articles for article (PubMed ID: 17846102)
21. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
Mulsant BH; Gharabawi GM; Bossie CA; Mao L; Martinez RA; Tune LE; Greenspan AJ; Bastean JN; Pollock BG
J Clin Psychiatry; 2004 Dec; 65(12):1708-14. PubMed ID: 15641877
[TBL] [Abstract][Full Text] [Related]
22. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
23. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
Mowla A; Pani A
J Clin Psychopharmacol; 2010 Feb; 30(1):40-3. PubMed ID: 20075646
[TBL] [Abstract][Full Text] [Related]
24. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
Currier GW; Simpson GM
J Clin Psychiatry; 2001 Mar; 62(3):153-7. PubMed ID: 11305699
[TBL] [Abstract][Full Text] [Related]
25. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
[TBL] [Abstract][Full Text] [Related]
26. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Deberdt WG; Dysken MW; Rappaport SA; Feldman PD; Young CA; Hay DP; Lehman DL; Dossenbach M; Degenhardt EK; Breier A
Am J Geriatr Psychiatry; 2005 Aug; 13(8):722-30. PubMed ID: 16085789
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of antipsychotics in dementia depended on the definition of patients and outcomes: a meta-epidemiological study.
Smeets CHW; Zuidema SU; Hulshof TA; Smalbrugge M; Gerritsen DL; Koopmans RTCM; Luijendijk HJ
J Clin Epidemiol; 2018 Sep; 101():17-27. PubMed ID: 29782995
[TBL] [Abstract][Full Text] [Related]
28. Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service.
Glass OM; Hermida AP; Hershenberg R; Schwartz AC
Curr Psychiatry Rep; 2020 Apr; 22(5):21. PubMed ID: 32285305
[TBL] [Abstract][Full Text] [Related]
29. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
Franco KN; Messinger-Rapport B
J Am Med Dir Assoc; 2006 Mar; 7(3):201-2. PubMed ID: 16503315
[TBL] [Abstract][Full Text] [Related]
31. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M
J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050
[TBL] [Abstract][Full Text] [Related]
32. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Freund-Levi Y; Jedenius E; Tysen-Bäckström AC; Lärksäter M; Wahlund LO; Eriksdotter M
Am J Geriatr Psychiatry; 2014 Apr; 22(4):341-8. PubMed ID: 24035407
[TBL] [Abstract][Full Text] [Related]
33. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
Lim HK; Kim JJ; Pae CU; Lee CU; Lee C; Paik IH
Neuropsychobiology; 2010; 62(2):81-6. PubMed ID: 20523078
[TBL] [Abstract][Full Text] [Related]
34. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
[TBL] [Abstract][Full Text] [Related]
35. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
[TBL] [Abstract][Full Text] [Related]
36. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Katz IR; Jeste DV; Mintzer JE; Clyde C; Napolitano J; Brecher M
J Clin Psychiatry; 1999 Feb; 60(2):107-15. PubMed ID: 10084637
[TBL] [Abstract][Full Text] [Related]
37. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
38. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
[TBL] [Abstract][Full Text] [Related]
39. Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.
Mueller C; John C; Perera G; Aarsland D; Ballard C; Stewart R
Eur J Epidemiol; 2021 Jan; 36(1):89-101. PubMed ID: 32415541
[TBL] [Abstract][Full Text] [Related]
40. Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Herrmann N; Rivard MF; Flynn M; Ward C; Rabheru K; Campbell B
J Neuropsychiatry Clin Neurosci; 1998; 10(2):220-3. PubMed ID: 9608413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
